The findings illuminate how the SARS-CoV-2 (COVID-19) pandemic has impacted the chronic patient population, and identifies opportunities to improve the health and wellbeing of those facing the greatest threat from the ongoing crisis.
Currently, six out of 10 adults in the US manage at least one chronic condition.
Care for this population is one of the most significant drivers of the nation's annual healthcare costs, which topped USD 3.5tn in 2018.
The survey focused on respondents managing chronic conditions such as diabetes, hypertension, and asthma, and the findings show that COVID-19 has significantly impacted their ability to manage their conditions.
The results also shine a light on multiple opportunities to better support this vulnerable patient population.
The survey indicates that the COVID-19 pandemic has had a significant effect on the chronic condition population by delaying access to care and exacerbating mental health challenges. Specific findings include:
More than half (57%) of respondents have delayed receiving healthcare services due to the pandemic at either their own discretion or that of their doctor and one in four (26%) patients have had trouble accessing their doctor.
Additionally, more than half of respondents report that they have not been provided a healthcare regimen by their doctor to effectively manage their condition, and more than one third (38%) are not fully confident in their ability to manage their chronic condition.
When respondents were asked if they were familiar with the term care management before the survey, more than one third (37%) said they were not.
This suggests a critical opportunity to raise awareness for services that can assist chronic condition patients during these difficult times.
People with chronic conditions are motivated to improve management of health, but unaware of solutions
As a result of the COVID-19 pandemic, Americans living with chronic conditions are motivated to take better control of managing their health. When surveyed on the appeal of using virtual care management as a solution to support health regimen adherence, respondents were strongly in favor:
A majority of chronic condition patients (74%) indicated that the pandemic has motivated them to take better control of managing their health.
More than two thirds (68%) think access to virtual support from a care management team would help them to more effectively adhere to their prescribed healthcare regimen.
This includes 61% of people over 45 years old and 79% of people under 29 years old, implying broader adoption by younger generations but broad appeal across generations.
66% of respondents (74% under the age of 29) would use a virtual care management team to manage mental health difficulties brought about by COVID-19.
As the emotional effects of the COVID-19 pandemic continue to be felt for months to come, health plans will have an important role to play in providing care management services for the chronic patient population to ensure their physical and mental wellbeing is addressed.
As healthcare moves toward a value-based model, collaboration between providers and health plans will be essential to holistic management of chronic disease.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes